Abstract
The use of single maintenance and reliver therapy (SMART) is proven to lower rates of asthma exacerbations across all stages of asthma severity and lowers exposure to the overall corticosteroids in comparison to conventional therapy. We surveyed providers who treat asthma and elicited barriers to prescription of SMART with the aim of identifying strategies for wider implementation.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
